Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telacebec in Buruli Ulcer
NCT06481163Phase 2Recruiting
- Sponsor
- Barwon Health
- Start
- Jul 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Telacebec in Buruli ulcer (BU), sponsored by Barwon Health. Primary endpoint: Rate of complete lesion healing at 52 weeks. Started Jul 2024; status: recruiting.
02
Drugs
Telacebec
03
Conditions
Buruli ulcer (BU)
Beyond the preview
Go deeper on NCT06481163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481163.